Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study by Mohty, Mohamad et al.
Original StudyMultiple Myeloma Treatment in Real-world
Clinical Practice: Results of a Prospective,
Multinational, Noninterventional Study
Mohamad Mohty,1 Evangelos Terpos,2 Maria-Victoria Mateos,3 Michele Cavo,4
Sandra Lejniece,5 Meral Beksac,6 Mohamed Amine Bekadja,7 Wojciech Legiec,8
Meletios Dimopoulos,2 Svetlana Stankovic,9 Maria Soledad Durán,10
Valerio De Stefano,11 Alessandro Corso,12 Yulia Kochkareva,13 Edward Laane,14
Christian Berthou,15 Hans Salwender,16 Zvenyslava Masliak,17 Valdas Peceliunas,18
Wolfgang Willenbacher,19 João Silva,20 Vernon Louw,21 Damir Nemet,22
Zita Borbényi,23 Uri Abadi,24 Robert Schou Pedersen,25 Peter Cernelc,26
Anna Potamianou,27 Catherine Couturier,28 Caroline Feys,29
Florence Thoret-Bauchet,28 Mario Boccadoro,30 on behalf of the EMMOS
Investigators
Abstract
Multiple myeloma (MM) remains an incurable disease, with little information available on its management in
real-world clinical practice. The results of the present prospective, noninterventional observational study
revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform
health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of
protocols to improve the outcomes of patients with MM.Poster presented at the 57th Annual Meeting of the American Society of Hematology,
December 5-8, 2015, Orlando, FL. Additional presentations of preﬁnal data were given
at the 2014 and 2015 European Hematology Association annual meetings, 2014
European School of Haematology annual meeting, and 2013 and 2015 International
Myeloma Workshops.
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MM Treatment in Real-world Clinical PracticeBackground: The present prospective, multinational, noninterventional study aimed to document and describe real-
world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult
patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site
recruitment model was applied to minimize the selection bias; enrollment was stratiﬁed by country, region, and
practice type. The patient medical and disease features, treatment history, and remission status were recorded at
baseline, and prospective data on treatment, efﬁcacy, and safety were collected electronically every 3 months.
Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell
transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%,
21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and  4, respectively. In
the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without
thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib,
and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment,
respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and  4 were 45% and 37%,
30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%,
and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64%
to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and
36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide.
Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to
manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving
treatment recommendations. Our results provide insight into associated clinical beneﬁts.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 10, e401-19 ª 2018 The Authors. Published by Elsevier Inc. This is an
open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Multiple myeloma (MM) is a common hematologic malignancy,
with an annual incidence of w86,000 cases worldwide (6.6 cases/
100,000 persons annually).1,2 Survival outcomes have improved
markedly in recent years owing to advances in our understanding of
MM disease biology, earlier detection, and improved treatment
strategies.3 The introduction of novel agents, such as bortezomib,
thalidomide, and lenalidomide, has contributed considerably to
these improved outcomes.3-5 However, despite these advances, MM
remains an incurable disease that typically follows a variable,
chronically relapsing course.6 Thus, many patients will require
multiple lines of therapy.4,5,7
The treatment landscape in MM is rapidly evolving. In 2010, the
main novel agents approved for use were bortezomib, lenalidomide
(after  1 previous line), and thalidomide. Since then, 6 novel
agents (ie, pomalidomide, carﬁlzomib, panobinostat, daratumumab,
ixazomib, elotuzumab) have been approved, and the indications for
both bortezomib and lenalidomide have been expanded. Although
the focus on the development of new therapies in clinical trials is
strong, limited real-world data are available on the treatment of MM
from a broad regional perspective.8-13 Therefore, the noninterven-
tional, multinational Europe, Middle East and Africa Multiple
Myeloma Observational Study (EMMOS; ClinicalTrials.gov iden-
tiﬁer, NCT01241396) was initiated in 2010 to capture real-world
data from multiple countries regarding MM treatment practices
and outcomes at different stages of the disease. Numerous types of
treatment centers were included in the EMMOS to provide robust
data regarding MM therapy in the real world.- Clinical Lymphoma, Myeloma & Leukemia October 2018Patients and Methods
Patients and Study Design
The present study was a prospective, noninterventional, multi-
center, observational study performed to document the use of
different treatment protocols and resource usage for MM in routine
clinical practice. Adult patients initiating any new therapy for MM
from October 2010 to October 2012 were consecutively enrolled in
the EMMOS registry, regardless of the therapy type or treatment
line at enrollment. Patients who were starting an investigational
drug at screening and patients who had received a new line of
therapy during the study if that new line was a part of a clinical
study were excluded. To minimize the selection bias, a multistage
site/patient recruitment model was applied. Enrollment occurred at
sites across Europe, the Middle East, and Africa and was stratiﬁed by
country, region, and practice type (academic, local, private, or
regional). The number of sites selected per country was proportional
to the overall population estimate of MM prevalence in each
country using the GLOBOCAN 2002 data.14,15 Each site had an
enrollment target to ensure that a representative number of patients
from each geographic location and practice type were enrolled. A
full list of the EMMOS investigators can be found in the
Supplemental Appendix (available in the online version).
Because the present study was a noninterventional study, patient
participation had no effect on their treatment course, and all
therapy-related questions were decided by the treating physician.
The appropriate independent ethics committees and institutional
review boards of all participating countries approved the present
study, which was conducted in accordance with the Declaration of
Mohamad Mohty et alHelsinki, Good Clinical Practice guidelines, and applicable regula-
tory requirements. An advisory board oversaw the conduct of the
study and monitored the data on an ongoing basis. All the patients
provided written informed consent.
Objectives and Assessments
The primary objective of the EMMOS was to document and
describe current treatment regimens and disease progression in pa-
tients with MM. The secondary objectives involved understanding
the MM patient population included in the present study (evalua-
tion of patient demographic data and disease characteristics), and
the extent to which the results of clinical trials can be applied to the
wider MM patient community. Additional objectives included
documenting and comparing the usage, effectiveness, and safety
proﬁles of the current MM treatment regimens.
The primary efﬁcacy endpoint was the best response to each line
of treatment (deﬁned as the greatest level of response achieved with
a treatment line). The responses were assessed and recorded after
each cycle by the treating physician; no predeﬁned response criteria
were mandated. The other efﬁcacy endpoints included time-to-
event analyses, such as the time to next treatment (TTNT; start-
ing from the beginning of the previous treatment), treatment-free
interval (TFI; starting from the end of the previous treatment),
and the treatment-free ratio (TFR; ratio of TFI to the duration of
the line preceding the TFI). The TFR, calculated as TFI/(TTNT 
TFI), was used to evaluate the treatment-free time, considering the
duration of the preceding treatment. A greater TFR indicates that
the patient spent more time treatment free than being treated,
which might result in improved quality of life. Overall survival was
also assessed; however, these data were not sufﬁciently mature at the
study end and were not included in the present report.
Data Collection
At enrollment in the study (baseline), retrospective data
(including patient demographic data and disease features, MM
treatment history, and remission status) were captured by a review
of the patients’ medical records (Supplemental Table 1; available in
the online version). During the prospective phase of the study, the
data regarding MM treatments and adverse events (AEs) were
captured electronically every 3 months, except for serious AEs,
which were reported within 24 hours of knowledge of the event.
The responses were captured as close to the start of each cycle as
possible, at the investigator’s discretion. Data collection ended 2
years after the last patient was enrolled.
Statistical Analysis
Because the study was observational, no formal statistical hypotheses
were tested. The target sample size was 2665 patients, which
represents  5% of the applicable population of patients with MM
treated within the participating countries. The data were analyzed in the
full set (deﬁned as all patientsmeeting the inclusion and exclusion criteria
who had received  1 prospective line of treatment) and according to
whether the patients had undergone stem cell transplantation (SCT)
during any prospective or retrospective line of treatment (SCT vs. non-
SCT patients). In addition, for the outcomes, the patient data were
analyzed stratiﬁed by the treatment received (thalidomide- orlenalidomide-based regimen, no bortezomib; bortezomib plus
thalidomide/lenalidomide-based regimen; bortezomib-based regimen,
no thalidomide/lenalidomide; other, no bortezomib or thalidomide/
lenalidomide). In each group (SCT vs. non-SCT), the treatment line
number was counted from diagnosis rather than from entry into the
study. The data were summarized descriptively, except where stated;
time-to-event endpoints were analyzed using theKaplan-Meiermethod.
The reported data on treatments, response, safety, and efﬁcacy were
from the prospective phase of the study, deﬁned as the period from
baseline to patient withdrawal or completion of the study. An MM
treatment regimen was deﬁned as  1 antineoplastic agent, gluco-
corticoid, or other medication prescribed forMM tumor reduction. A
line of treatment was deﬁned as 1 cycle of a plannedMM treatment
regimen and could include  1 planned cycle of single-agent or
combination therapy or a sequence of combination therapy admin-
istered in a planned schedule (eg, induction therapy followed by high-
dose chemotherapy/SCT and maintenance).16 We grouped treat-
ments within a given line as follows: (1) treatment received during a
line was deﬁned according to the regimen received in cycle 1 of that
line; and (2) because it was possible to receive multiple drug combi-
nations within a single treatment line, the line grouping was also
categorized according to the drugs received at any time during that line
(eg, during induction, high-dose chemotherapy, and maintenance).
The ﬁrst method sought to better identify the treatments received
during induction, rather than sequentially within a given line; the
second method was used for the analyses of efﬁcacy and safety.
Results
Patients
From October 2010 to October 2012, 2358 patients from 22
countries across Europe, the Middle East, and Africa were enrolled
(Figure 1). The target enrollment of 2665 patients was not met owing
to the high number of interventional studies initiated during this period
and the exclusion of patients enrolled in such from the EMMOS reg-
istry. Most patients were enrolled in academic (43.7%) or regional
(29.1%) study sites, and most were enrolled at sites in Europe. Of the
2358 patients, 51% were male and 43.4% were aged > 65 years at
diagnosis (Table 1), in line with epidemiologic expectations.
A total of 775 patients (33%) underwent SCT within 1 of their
treatment lines (SCT group) and 1583 (67%) did not (non-SCT
group; Table 1). The number of evaluable patients in the SCT and
non-SCT groups stratiﬁed by line of therapy at study entry is listed
in Table 1. The median duration of study participation was 27.7
months (interquartile range [IQR], 19.7-32.8 months) in the SCT
group and 24.5 months (IQR, 11.8-30.3 months) in the non-SCT
group. The ﬁnal data collection was on November 26, 2014.
As expected, the patients in the SCT group were younger at
diagnosis than those in the non-SCT group (90.3% of the SCT
patients were aged  65 years compared with 40.1% of the non-
SCT patients). A lower percentage of SCT patients had Interna-
tional Staging System (ISS) stage III disease at baseline compared
with the non-SCT population (34.6% vs. 44.3%, respectively). The
proportion of patients with a history of bone lesions (71.5% vs.
67.5%) and the proportion of patients requiring dialysis (12.7% vs.
17.5%) in the SCT and non-SCT groups, respectively, were in line
with current expectations for the MM population.17 CytogeneticClinical Lymphoma, Myeloma & Leukemia October 2018 - e403
Figure 1 Patient Disposition and Enrollment Stratiﬁed By Country and Site Type. Patients Who Underwent Stem Cell Transplantation
(SCT) Within This Line: Line 1, n [ 299; Line 2, n [ 133; Line 3, n [ 76; Line 4, n [ 21; Line 5D, n [ 29. yIncluded
1 Patient Who Was Withdrawn From the Study Because of an Undocumented Screen Failure
775 patients who received an SCT at any time 
during their treatment course*
Line 1 n = 378 
Line 2 n = 161
Line 3 n = 107
Line 4 n = 57
Line 5+ n = 63
Completed: n = 491
Prematurely terminated: n = 282
• Adverse event leading to death: n = 199
• Lost to follow up: n = 53
• Withdrawal of consent: n = 10
• Death (not due to AE): n = 7
• Investigator decision: n = 4
• Administration reasons: n = 4
• Other: n = 5
1583 patients who did not receive an SCT at 
any time during their treatment course
Line 1 n = 897
Line 2 n = 319
Line 3 n = 184
Line 4 n = 85
Line 5+ n = 81
Completed: n = 715
Prematurely terminated: n = 867
• Adverse event leading to death: n = 571
• Lost to follow up: n = 137
• Withdrawal of consent: n = 48
• Death (not due to AE): n = 57
• Investigator decision: n = 19
• Administration reasons: n = 23
• Other: n = 12†
Sites, n (%) Patients per site, n (%)
All sites 234 2358
By site type
Academic 95 (40.6) 1031 (43.7)
Regional 72 (30.8) 687 (29.1)
Local 27 (11.5) 266 (11.2)
Private 40 (17.1) 374 (15.9)
By country
Italy 48 (20.5) 467 (19.8)
Germany 43 (18.4) 360 (15.3)
Ukraine 21 (9.0) 212 (9.0)
Spain 25 (10.7) 208 (8.8)
Russia 19 (8.1) 206 (8.7)
Poland 16 (6.8) 182 (7.7)
France 15 (6.4) 155 (6.6)
Turkey 10 (4.3) 126 (5.3)
Algeria 6 (2.6) 81 (3.4)
Greece 4 (1.7) 53 (2.2)
Israel 5 (2.1) 47 (2.0)
Latvia 1 (< 1) 44 (1.9)
Hungary 4 (1.7) 35 (1.5)
South Africa 4 (1.7) 31 (1.3)
Estonia 2 (< 1) 28 (1.2)
Lithuania 2 (< 1) 24 (1.0)
Macedonia 1 (< 1) 23 (1.0)
Austria 2 (< 1) 20 (< 1)
Portugal 2 (< 1) 19 (< 1)
Denmark 2 (< 1) 14 (< 1)
Croatia 1 (< 1) 13 (< 1)
Slovenia 1 (< 1) 10 (< 1)
2358 patients enrolled (Full analysis set)
Line 1 n = 1275
Line 2 n = 480
Line 3 n = 291
Line 4 n = 142
Line 5+ n = 144
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Table 1 Patient Demographics and Disease Characteristics at Baseline
Variable
SCT Received
All Patients (n [ 2358)Yes (n [ 775) No (n [ 1583)
Gender
Male 447 (58) 764 (48) 1211 (51)
Female 328 (42) 819 (52) 1147 (49)
Age at diagnosis, y
Median 57 68 63
IQR 51-62 60-74 56-71
Range 25-74 32-91 25-91
Aged > 65 y at diagnosis, y (%) 75 (9.7) 949 (60) 1024 (43)
Age at study entry, y
Median 59 70 65
IQR 53-64 61-75 58-73
Range 28-79 33-91 28-91
Age  65 y at study entry, %
Overall 80 36 NA
Treatment line at study entry
1 87 36
2 76 33
3 72 35
 4 71 39
Disease stage at study entrya
ISS stage only 187 (24.1) 313 (19.7) 500 (21)
Durie-Salmon stage only 302 (40.8) 799 (51.9) 1101 (48)
ISS, Durie-Salmon stage 192 (25.9) 333 (21.6) 525 (22)
Not available 60 (8.1) 94 (6.1) 154 (7)
Missing 34 (4.3) 44 (2.7) 78 (3)
ISS stage at study entrya 379 646 1025
I 119 (31.4) 135 (20.9) 254 (25)
II 129 (34.0) 225 (34.8) 354 (35)
III 131 (34.6) 286 (44.3) 417 (41)
II/III stratiﬁed by therapy line at study entryb NA
1 68 80
2 71 81
3 60 81
 4 71 74
Durie-Salmon disease stage at study entrya 494 1132 1626
1 51 (10.3) 91 (8.0) 142 (9)
2 101 (20.4) 301 (26.6) 402 (25)
3 342 (69.2) 740 (65.4) 1082 (67)
2/3 stratiﬁed by therapy line at study entryc
1 90 91 NA
2 92 90 NA
3 85 95 NA
 4 92 91 NA
Cytogeneticsa 337 (43.6) 333 (21.0) 670 (28)
High risk 60 (17.8) 45 (13.5) 110 (15)
Del17p 30 (8.9) 25 (7.5) 55 (8)
t(4;14) 30 (8.9) 20 (6.0) 50 (7)
Del13 75 (22.3) 55 (16.5) 130 (19)
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Table 1 Continued
Variable
SCT Received
All Patients (n [ 2358)Yes (n [ 775) No (n [ 1583)
Other 108 (32.0) 120 (36.0) 228 (34)
Normal (no speciﬁc ﬁndings) 146 (43.3) 157 (47.1) 303 (45)
Baseline laboratory evaluationsd 2332
Serum b2M, mg/L NA NA 1445 (62.0)
< 3.5 NA NA 550 (38.1)
3.5 to < 5.5 NA NA 375 (26.0)
 5.5 NA NA 520 (36.0)
Serum LDH, U/L NA NA 1714 (73.5)
< 300 NA NA 1143 (66.7)
 300 NA NA 571 (33.3)
MM-related medical history at study entrya
History of bone lesion 554 (71.5) 1068 (67.5) 1622 (69)
History of bone lesion stratiﬁed by line at study entry, %
1 66 64 NA
2 74 72 NA
3 77 75 NA
 4 80 70 NA
Severe renal impairment 102 (13.2) 292 (18.4) 394 (17)
Dialysis dependent 13 (12.7) 51 (17.5) 64 (16)
History of heart failure 52 (6.7) 280 (17.7) 332 (14)
MM treatment line at study entry
1 378 (49) 897 (57) 1275 (55)
2 161 (21) 319 (20) 480 (21)
3 107 (14) 184 (12) 291 (12)
4 57 (7) 85 (5) 142 (6)
 5 63 (8) 81 (5) 144 (6)
Missinge 9 17 26
Data presented as n (%), with all percentages calculated using the total number minus any missing values.
Abbreviations: b2M ¼ b2-microglobulin; Del ¼ deletion; IQR ¼ interquartile range; ISS ¼ International Staging System; LDH ¼ lactate dehydrogenase; MM ¼ multiple myeloma; SCT ¼ stem cell
transplantation; t ¼ translocation.
aPercentages determined from number of patients with Durie-Salmon stage or number of patients with cytogenetic data.
bPercentages calculated from number of patients with available staging data (SCT: line 1, n ¼ 225; line 2, n ¼ 66; line 3, n ¼ 35; line  4, n ¼ 48; total, n ¼ 374; non-SCT: line 1, n ¼ 412; line
2, n ¼ 118; line 3, n ¼ 56; line  4, n ¼ 54; total, n ¼ 640).
cPercentages calculated from number of patients with available staging data (SCT: line 1, n ¼ 233; line 2, n¼ 96; line 3, n¼ 75; line  4, n ¼ 83; total, n ¼ 487; non-SCT: line 1, n¼ 641; line 2,
n ¼ 220; line 3, n ¼ 138; line  4, n ¼ 120; total, n ¼ 1119).
dBaseline b2M and LDH summarized for the full analysis set as the number and percentage of patients with an MM treatment line at baseline ( 75 days) and available results; the percentages for the
categories within b2M and LDH were calculated using the number of subjects with available results.
eMissing patients did not receive treatment at study entry (within the 75-day baseline window) because of the following: treatment planned but not received, observation only (protocol deviation), or
start date missing and imputed date therefore outside the baseline window.
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situ hybridization were evaluated in 670 of 2358 patients (28%)
overall. These assessments were performed signiﬁcantly more
frequently in the SCT than in the non-SCT patients (337 [43.5%]
and 333 [21.0%] patients, respectively). Approximately one half of
the patients in the SCT and non-SCT groups were previously
untreated at study entry.
MM Therapies
Frontline Therapy. Of the 380 patients who underwent SCT after
study enrollment, 299 (79%) received it as a component of their
ﬁrst-line therapy, and 81 underwent SCT-based therapy only in
salvage lines (Table 2). Of the 299 frontline SCT patients, most- Clinical Lymphoma, Myeloma & Leukemia October 2018received autologous SCT (97%), and most had a single transplant
(81%; Table 2). The most common induction therapies for patients
with frontline SCT (cycle 1 regimens) were VTD (bortezomib,
thalidomide, dexamethasone; n ¼ 95), VD (bortezomib, dexa-
methasone; n ¼ 56), VCD (bortezomib, cyclophosphamide, dexa-
methasone; n ¼ 49), vincristine, doxorubicin, bortezomib,
dexamethasone (n ¼ 26), and CDT (cyclophosphamide, dexa-
methasone, thalidomide; n ¼ 26).
During their ﬁrst cycle, most patients in the overall SCT pop-
ulation received a bortezomib-based regimen without thalidomide/
lenalidomide (n ¼ 170; 45%) or a bortezomib plus thalidomide/
lenalidomide-based regimen (n ¼ 114; 30%; Table 2). In total,
159 SCT patients (42%) received a bortezomib plus thalidomide/
Table 2 Frontline Therapy for SCT and Non-SCT Patients Recorded During Prospective Data Collection Phasea
Treatment SCT Patients (n [ 380) Non-SCT Patients (n [ 906)
Regimens received during cycle 1 of frontline therapy
Thalidomide/lenalidomide-based, no bortezomib 46 (12.1) 160 (17.7)
MPT 0 (0) 68 (7.5)
CDT 34 (8.9) 56 (6.2)
Bortezomib plus thalidomide/lenalidomide-based 114 (30.0) 34 (3.8)
VTD 100 (26.3) 28 (3.1)
VRD 5 (1.3) 2 (0.2)
Bortezomib-based, no thalidomide/lenalidomide 170 (44.7) 491 (54.2)
VD 70 (18.4) 122 (13.5)
VCD 56 (14.7) 61 (6.7)
VMP 3 (0.8) 218 (24.1)
Other, no bortezomib or thalidomide/lenalidomide 50 (13.2) 221 (24.4)
MP 0 65 (7.2)
Vincristine, doxorubicin, dexamethasone 29 (7.6) 37 (4.1)
Regimens received at any point during frontline therapy
Thalidomide/lenalidomide-based, no bortezomib 53 (13.9) 177 (19.5)
Bortezomib plus thalidomide/lenalidomide-based 159 (41.8) 61 (6.7)
Bortezomib-based, no thalidomide/lenalidomide 131 (34.5) 478 (52.8)
Other, no bortezomib or thalidomide/lenalidomide 37 (9.7) 190 (21.0)
Agents received during frontline therapy, n
Median 4 3
IQR 3-5 3-3
Range 1-10 1-7
Treatment duration, mo
Median 7.5 6.4
IQR 4.4-13.9 3.0-10.6
Range 0.1-132.5 0.03-51.9
SCT within frontline therapyb
Any SCT 299 NA
Autologous 291 (97.3) NA
Allogeneic 8 (2.7) NA
SCTs NA
1 242 (80.9) NA
2 57 (19.1) NA
For cycle 1 regimens, any combination for  10% of patients in SCT or non-SCT group was provided, with  2 regimens (most frequent) for each grouping.
Abbreviations: C ¼ cyclophosphamide; D ¼ dexamethasone; IQR ¼ interquartile range; M ¼ melphalan; P ¼ methylprednisolone/prednisolone/prednisone; R ¼ lenalidomide; SCT ¼ stem cell
transplantation; T ¼ thalidomide; V ¼ bortezomib.
aFor example, among the patients who entered the study at the point of receiving their ﬁrst therapy line.
bSCT was counted once per separate date recorded; a patient could have undergone > 1 (overall if in different lines and per line as a planned tandem transplant) during the study period.
Mohamad Mohty et allenalidomide-based regimen at any point during their frontline
regimen and 131 (35%) received a bortezomib-based regimen
without thalidomide/lenalidomide (Table 2). Thus, of the 170
patients who initiated cycle 1 with a bortezomib-based regimen that
did not include thalidomide/lenalidomide, 39 (23%) subsequently
received thalidomide/lenalidomide in later cycles of their frontline
therapy. Of those patients who initiated cycle 1 with an “other”
regimen (not containing bortezomib or thalidomide/lenalidomide),
13 (26%) received bortezomib (n ¼ 6) or thalidomide/lenalido-
mide (n ¼ 7) during subsequent cycles of frontline therapy. The
patients were treated for a median of 7.5 months (IQR, 4.4-13.9
months).In the non-SCT population, more than one half of patients
received a frontline bortezomib-based regimen without thalidomide/
lenalidomide during their ﬁrst cycle (54%) and 24% of patients
received a combination of “other” agents (Table 2). The most com-
mon combinations in the non-SCT group were VMP (bortezomib,
melphalan, prednisone) and VD. More than one half of the patients
received bortezomib at any time during their frontline therapy (59%),
including 53% who received a bortezomib-based regimen without
thalidomide/lenalidomide (Table 2). Of those patients who received a
bortezomib-based regimenwithout thalidomide/lenalidomide during
cycle 1, 13 subsequently received thalidomide/lenalidomide in later
cycles of their frontline therapy as maintenance. Of those patientsClinical Lymphoma, Myeloma & Leukemia October 2018 - e407
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e408who initiated cycle 1 with an “other” regimen, 31 were later treated
with either bortezomib (n ¼ 14) or thalidomide/lenalidomide
(n ¼ 17). Patients were treated in the frontline for a median of
6.4 months (IQR, 3.0-10.6 months).
Because the patient numbers were insufﬁcient to analyze the data
for frontline regimens per country, the data from countries classiﬁed
as having a high or low 60-year-old life expectancy using the World
Health Organization’s Global Health Observatory data, with the
patients grouped according to age ( 65 years vs. > 65 years) in the
SCT and non-SCT populations are listed in Supplemental Table 2
(available in the online version).
Salvage Therapies. In the SCT population, of the patients with
data collected prospectively for treatment lines 2, 3, or  4 (ﬁrst,
second, or later salvage, respectively), 45%, 33%, and 27% had
received a bortezomib-based regimen without thalidomide/lenali-
domide during that line, 12%, 8%, and 6% had received a borte-
zomib plus thalidomide/lenalidomide-based regimen, 30%, 35%,
and 27% had received a thalidomide/lenalidomide-based regimen
without bortezomib, and 13%, 24%, and 40% had received an
“other” regimen, respectively (Table 3). The most common com-
bination in lines 2, 3, and  4 was RD (lenalidomide, dexameth-
asone; 20%, 21%, and 13%, respectively; Table 3).
In the non-SCT group, 37% of the patients received a
bortezomib-based regimen without thalidomide/lenalidomide and
37% received a thalidomide/lenalidomide-based regimen without
bortezomib in their second-line treatment, with only 3% receiving a
second-line regimen containing both types of agents (Table 3). In
lines 3 and  4, 32% and 23%, respectively, received a
thalidomide/lenalidomide-based regimen without bortezomib, and
39% and 46%, respectively, were treated with a combination of
“other” agents. The frequently observed other salvage regimens in
lines 2, 3, and  4 included MP (melphalan plus methylprednis-
olone or prednisolone or prednisone; Table 3).
Data for salvage regimens from countries with either a high or
low 60-year-old life expectancy for both SCT and non-SCT
populations are listed in Supplemental Table 3 (available in the
online version).
Treatment Response
Frontline Therapy. In the SCT group, the best overall response rate
(ORR) at any time during frontline therapy was > 85% for patients
receiving bortezomib and/or thalidomide/lenalidomide, including 
50% rates of a very good partial response (VGPR) or better (Table 4).
The ORR for patients receiving other therapies was 71% and the
VGPR or better rate was 29%. In the non-SCT population, the ORR
was 80%, with 40% of the patients achieving a VGPR or better. For
patients treated with a thalidomide/lenalidomide-based regimen
without bortezomib, the ORR and VGPR or better rate was 64%
and 24%, respectively (Table 4). In those patients receiving other
combinations, the ORR was 51%, with only 10% achieving a VGPR
or better.
Salvage Therapy. In the SCT group, the ORR for patients
receiving a bortezomib plus thalidomide/lenalidomide-based regimen
was 78%, 83%, 60%, and 33% for treatment lines 2, 3, 4, and  5,- Clinical Lymphoma, Myeloma & Leukemia October 2018respectively. Similar data were observed across the other regimen
groups (Table 4). For treatment lines 2, 3, 4, and  5 in the non-
SCT group, the ORR was 68%, 60%, 45%, and 35%, respec-
tively, for patients treated with a bortezomib plus thalidomide/
lenalidomide-based regimen. Again, the data for the other regimen
groups were largely similar (Table 4). As seen with the frontline
regimens, the ORRs for the SCT group were greater than those for
the non-SCT population through line 4; however, in later lines (
5), the ORRs were similar overall in the SCT and non-SCT groups.
Efﬁcacy: Time-to-event Endpoints
Frontline Therapy. The patients in the SCT group who received a
thalidomide-based regimen, a bortezomib plus thalidomide-based
regimen, a bortezomib-based regimen without thalidomide/lenali-
domide, or ‘other’ regimens had a median TTNT of 29.4, 38.4,
23.6, and 5.7 months and a median TFI of 14.6, 28.5, 16.5, and
1.7 months, respectively (Table 5). The TFR appeared greater for
regimens typically not using a maintenance component or a treat-
to-progression approach, such as the ‘other’ category, which was
primarily vincristine, doxorubicin, dexamethasone induction in this
setting. Both the median TTNT and the median TFI were shortest
in this subgroup.
In the non-SCT population, the median TTNT for the patients
treated with a thalidomide-based regimen, a bortezomib plus
thalidomide-based regimen, a bortezomib-based regimen without
thalidomide/lenalidomide, or ‘other’ regimens was 17.7, 18.5, 22.0,
and 13.3 months, respectively (Table 5). The median TFI for the
patients who received a thalidomide-based regimen, a bortezomib
plus thalidomide-based regimen, or a bortezomib-based regimen
without thalidomide/lenalidomide was 3.71, 6.11, and 11.2 months,
respectively. For the patients treated with ‘other’ regimens, the me-
dian TFI was only 2.7 months, corresponding to a TFR of 0.91.
Salvage Therapy. In the SCT population, the patients who received
a bortezomib plus thalidomide-based regimen had a TTNT of 34.4
and 14.1 months in treatment lines 2 and 3, respectively (Table 5).
In lines 2, 3, 4, and  5, the patients treated with a thalidomide-
based regimen without bortezomib had a TTNT of 17.7, not
evaluable, 13.7, and 4.7 months, respectively. The corresponding
TTNT for patients receiving lenalidomide-based regimens without
bortezomib was 19.3, 22.6, 22.7, and 35.8 months. The corre-
sponding TTNT for patients receiving ‘other’ regimens was 17.2,
13.2, 7.4, and 10.4 months (Table 5). The TFR decreased with each
subsequent line, suggesting that patients were increasingly in need of
continuing with treatment as they received subsequent lines of
therapy. In the non-SCT group, a similar pattern of declining TTNT
and TFI with subsequent lines was observed (Table 5). The TFR also
decreased with each subsequent line of therapy.
Safety
In the SCTgroup, 77%of patients who had received a bortezomib-
based regimen without thalidomide/lenalidomide recorded  1
treatment-emergent AE (Supplemental Table 4; available in the on-
line version). Similar rates were observed for patients who received
bortezomib plus thalidomide- or lenalidomide-based regimens (83%
and 82%, respectively). Serious AEs were recorded in 21%, 16%, and
Table 3 Salvage Therapies for SCT and Non-SCT Patients Recorded During Prospective Data Collection Phasea and Based on Agents
Received During Cycle 1 of Each Line
Treatment
SCT Patients (n [ 395) Non-SCT Patients (n [ 677)
Line 2
(n [ 345)
Line 3
(n [ 288)
Line ‡ 4
(n [ 486)
Line 2
(n [ 805)
Line 3
(n [ 590)
Line ‡ 4
(n [ 935)
Regimens received during cycle 1 of each salvage
therapy line
Thalidomide/lenalidomide-based, no bortezomib 103 (29.9) 101 (35.1) 131 (27.0) 295 (36.6) 189 (32.0) 215 (23.0)
Bortezomib plus thalidomide/lenalidomide-based 41 (11.9) 23 (8.0) 30 (6.2) 20 (2.5) 13 (2.2) 34 (3.6)
Bortezomib-based, no thalidomide/lenalidomide 156 (45.2) 95 (33.0) 132 (27.2) 296 (36.8) 158 (26.8) 255 (27.3)
Other, no bortezomib or thalidomide/lenalidomide 45 (13.0) 69 (24.0) 193 (39.7) 194 (24.1) 230 (39.0) 431 (46.1)
Most prevalent combinations
First RD: 69 (20.0) RD: 61 (21.2) RD: 63 (13.0) RD: 163 (20.2) RD: 100 (16.9) VD: 92 (9.8)
Second VD: 65 (18.8) VCD: 25 (8.7) VD: 38 (7.8) VD: 140 (17.4) VD: 57 (9.7) RD: 71 (7.6)
Third VCD: 43 (12.5) ADV: 11 (3.8) VCD: 31 (6.4) VMP: 44 (5.5) MP: 39 (6.6) MP: 50 (5.4)
Fourth VTD: 25 (7.2) VRD: 9 (3.1) CD: 19 (3.9) VCD: 40 (5.0) VCD: 32 (5.4) VCD: 47 (5.0)
Treatment duration, mo
Median 4.4 3.7 3.5 4.6 3.9 3.0
IQR 2.3-8.8 1.6-7.0 1.1-7.2 2.3-8.2 1.6-7.9 1.0-6.6
Range 0.03-37.1 0.03-32.1 0.03-50.9b 0.03-44.0 0.03-46.9 0.03-36.1b
SCT within each line of salvage therapy
Any SCT 133 76 50 NA NA NA
Autologous 126 (94.7) 66 (86.8) 42 (84) NA NA NA
Allogeneic 7 (5.3) 10 (13.2) 8 (16) NA NA NA
SCTsc NA NA NA
1 123 (92.5) 71 (93.4) 47 (94) NA NA NA
2 10 (7.5) 5 (6.6) 3 (6) NA NA NA
Most prevalent treatment combinations (counted in  50 lines within each therapy line) for prospective MM treatment lines during the ﬁrst cycle in SCT or non-SCT group shown stratiﬁed by treatment
line; SCTs were counted only once per separate date recorded; thus, a patient could have undergone > 1 SCT (overall and per line) during the study period.
Abbreviations: A ¼ doxorubicin; C ¼ cyclophosphamide; D ¼ dexamethasone; M ¼ melphalan; MM ¼ multiple myeloma; P ¼ methylprednisolone/prednisolone/prednisone; R ¼ lenalidomide;
SCT ¼ stem cell transplantation; T ¼ thalidomide; V ¼ bortezomib.
aFor example, if a patient entered the study to begin treatment line 3, these data included the treatment regimens received by the patient at line 3 (and any subsequent lines) but not the information
collected retrospectively for previous treatment (line 1, line 2) before study enrollment.
bData for treatment line 4 only.
cTandem SCT.
Mohamad Mohty et al30% of patients who had received a bortezomib-based regimen
without thalidomide/lenalidomide, a bortezomib plus thalidomide-
based regimen, or a bortezomib plus lenalidomide-based regimen,
respectively (Supplemental Table 4; available in the online version).
Similar rates were also observed in non-SCT patients in these treat-
ment groups, although the numbers were small in some cases. The
rates of AEs were lower for patients who had received regimens
without bortezomib, thalidomide, or lenalidomide (43% in the SCT
and 53% in the non-SCTpatients; Supplemental Table 4; available in
the online version). In the SCT group, the incidence of peripheral
neuropathy (PN) or peripheral sensory neuropathy (PSN) in those
regimens without bortezomib (all lines) was < 5%. For patients
receiving a bortezomib-based regimen with thalidomide, with lena-
lidomide, or without thalidomide/lenalidomide, the corresponding
rates were 12.9% (PN; PSN 10.8%), 6.3% (PSN), and 5% (PN; PSN
6.2%), respectively. In the non-SCT group, a similar pattern was
observed. The incidence of PN (or PSN) for patients receiving a
bortezomib-based regimen with thalidomide, with lenalidomide, or
without thalidomide/lenalidomide were < 5% (PN), 7.0% (PSN),
and 6.6% (PN; PSN 6.0%), respectively. However, the incidence ofPN for patients receiving thalidomide without bortezomib was 9.7%.
Owing to the cumulative dose-related nature of both bortezomib-
induced and thalidomide-induced PN and the absence of data on
the duration of treatment for individual regimens, it is possible that
the PN rates were affected by the treatment durations used for
different regimens in different settings, and these data should be
interpreted accordingly.
Discussion
To the best of our knowledge, the results from the EMMOS
provide the ﬁrst comprehensive information on the baseline
characteristics and treatment of patients withMM treated in multiple
countries across Europe, the Middle East, and Africa. This real-world
evidence, which differs, by deﬁnition, from the evidence obtained
through clinical trials, permits an evaluation of the safety and efﬁcacy
of MM treatments in daily practice compared with those reported
from controlled clinical trials and allows for interpretation on the
generalizability of results obtained from such trials compared with
those achievable in routine practice. As a prospective, multinational
registry, the EMMOS also provides an opportunity to evaluate real-Clinical Lymphoma, Myeloma & Leukemia October 2018 - e409
Table 4 Best Response for SCT and Non-SCT Patients Stratiﬁed by Treatment Line and Type (at Any Point in Line) in Prospective
Study Phase (Patients With Available Response Data)
Response
SCT Patients Non-SCT Patients
Patients, n OR
VGPR or
Better Patients, n OR
VGPR or
Better
Line 1
Thalidomide/lenalidomide-based, no bortezomib 48 45 (94) 29 (60) 140 90 (64) 34 (24)
Bortezomib plus thalidomide/lenalidomide-based 119 115 (97) 92 (77) 40 34 (85) 21 (53)
Bortezomib-based, no thalidomide/lenalidomide 111 95 (86) 57 (51) 380 302 (79) 148 (39)
Other, no bortezomib or thalidomide/lenalidomide 28 20 (71) 8 (29) 153 78 (51) 15 (10)
Line 2
Thalidomide/lenalidomide-based, no bortezomib 69 52 (75) 25 (36) 223 132 (59) 61 (27)
Bortezomib plus thalidomide/lenalidomide-based 40 31 (78) 22 (55) 22 15 (68) 7 (32)
Bortezomib-based, no thalidomide/lenalidomide 117 87 (74) 54 (46) 233 153 (66) 67 (29)
Other, no bortezomib or thalidomide/lenalidomide 28 20 (71) 15 (54) 146 74 (51) 18 (12)
Line 3
Thalidomide/lenalidomide-based, no bortezomib 74 41 (55) 19 (26) 134 64 (48) 23 (17)
Bortezomib plus thalidomide/lenalidomide-based 18 15 (83) 9 (50) 20 12 (60) 4 (20)
Bortezomib-based, no thalidomide/lenalidomide 66 38 (58) 22 (33) 116 66 (57) 30 (26)
Other, no bortezomib or thalidomide/lenalidomide 41 22 (54) 11 (27) 176 72 (41) 20 (11)
Line 4
Thalidomide/lenalidomide-based, no bortezomib 37 24 (65) 9 (24) 76 27 (36) 9 (12)
Bortezomib plus thalidomide/lenalidomide-based 10 6 (60) 1 (10) 11 5 (45) 3 (27)
Bortezomib-based, no thalidomide/lenalidomide 45 22 (49) 14 (31) 89 39 (44) 16 (18)
Other, no bortezomib or thalidomide/lenalidomide 38 10 (26) 7 (18) 116 33 (28) 4 (3)
Line  5
Thalidomide/lenalidomide-based, no bortezomib 46 20 (43) 8 (17) 96 39 (41) 13 (14)
Bortezomib plus thalidomide/lenalidomide-based 12 4 (33) 4 (33) 17 6 (35) 2 (12)
Bortezomib-based, no thalidomide/lenalidomide 55 23 (42) 8 (15) 111 39 (35) 4 (4)
Other, no bortezomib or thalidomide/lenalidomide 83 24 (29) 12 (15) 196 37 (19) 5 (3)
Percentages calculated from total number per type of therapy, excluding any missing or not evaluable patients.
Abbreviations: OR ¼ overall response; SCT ¼ stem cell transplantation; VGPR ¼ very good partial response.
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large, multinational, multisite analysis provide important evidence to
add to the increasing number of reports from analyses of MM treat-
ment in the real-world setting.8-13
The reliability of the EMMOS registry is supported by the baseline
demographic data and clinical characteristics of the study cohort,
which were as expected for a MM population. For example, almost
80% of patients with MM have been reported to have radiologic
evidence of skeletal involvement.18 In our study,w70% of patients
reported a history of bone lesions at study entry. Equally, MM is well
known as a disease that predominantly occurs in an older popula-
tion.10 In the non-SCT group in the EMMOS, the median age at
study entry was 70 years, with that in the SCT group slightly younger
at 59 years, as expected, given that younger age can be a key factor in
determining SCT eligibility.10 Nevertheless, we acknowledge that a
reporting bias might be present toward patients who were younger or
ﬁtter at diagnosis owing to the inclusion of patients who had received
multiple previous lines of therapy—older or more frail patients might
not have survived long enough to receive several lines of treatment. In
contrast, a slight reporting bias might have been present owing to the
omission from the EMMOS of patients already enrolled in the large- Clinical Lymphoma, Myeloma & Leukemia October 2018number of prospective studies taking place concurrently, who
potentiallymight have been younger and/or ﬁtter than the nonclinical
trial population eligible for the EMMOS.
In terms of treatment, data from the EMMOS have shown that
bortezomib was the most commonly used backbone agent in the
frontline setting, with 75% and 58% of SCT and non-SCT patients
receiving a bortezomib-based regimen with or without thalidomide/
lenalidomide. Patients in the SCT group were more likely to receive
a frontline combination of VTD than were their counterparts in the
non-SCT group (30% vs. 4%, respectively). In contrast, the VMP
regimen was more commonplace in the latter group (1% vs. 24%),
reﬂecting the different standard-of-care regimens in these settings in
Europe. In the salvage setting, the use of bortezomib-based and
thalidomide/lenalidomide-based regimens appeared similar, with
the exception of second-line therapy for SCT patients. In both the
SCT and the non-SCT groups, the receipt of ‘other’ treatments and
the diversity of combinations within this category were increasingly
common in later lines, suggesting a lack of overall consensus for the
best treatment practices in advanced disease. These ﬁndings also
reﬂect the limited treatment options at the time of the EMMOS,
with many patients “exhausting” their bortezomib- and/or
Table 5 Time-to-event Endpoints for SCT and Non-SCT Patients Stratiﬁed By Treatment Line and Type Received at Any Point During Linea
Variable
SCT Patients Non-SCT Patients
Line, n/N (%)
Median TTNT,
mo (95% CI)
Median TFI,
mo (95% CI) TFR Line, n/N (%)
Median TTNT,
mo (95% CI)
Median TFI,
mo (95% CI) TFR
Line 1b
Thalidomide-based 26/51 (51) 29.4 (15.51-NE) 14.6 (0.99-NE) 1.55 89/158 (56) 17.7 (15.1-22.1) 3.71 (2.30-5.13) 0.71
Bortezomib plus lenalidomide-based 6/27 (22) NE (NE-NE) NE (NE-NE) 0.67 4/19 (21) NE (NE-NE) 16.4 (0.07-16.4) 0.35
Bortezomib plus thalidomide-based 42/124 (34) 38.4 (38.4-NE) 28.5 (17.9-34.2) 1.68 18/35 (51) 18.5 (8.28-31.4) 6.11 (1.38-24.2) 1.56
Bortezomib-based, no thalidomide/
lenalidomide
69/125 (55) 23.6 (21.5-37.6) 16.5 (15.4-23.0) 2.52 236/450 (52) 22.0 (20.0-24.2) 11.2 (10.0-13.8) 1.71
Other,c no bortezomib or thalidomide/
lenalidomide
25/32 (78) 5.7 (2.6-9.7) 1.7 (1.0-2.7) 2.80 102/167 (61) 13.3 (9.5-17.1) 2.7 (1.7-5.5) 0.91
Line 2d
Thalidomide-based 10/19 (53) 17.7 (10.3-NE) 11.8 (0.13-NE) 2.29 42/80 (53) 15.2 (10.5-23.6) 2.96 (1.22-7.49) 0.72
Lenalidomide-based 39/80 (49) 19.3 (13.2-36.1) 2.37 (1.25-5.09) 0.56 64/182 (35) 27.1 (17.6-NE) 7.23 (2.53-14.5) 0.64
Bortezomib plus lenalidomide-based 8/18 (44) 21.3 (5.62-NE) 5.29 (0.76-NE) 0.89 3/8 (38) 20.1 (10.7-NE) 14.8 (0.33-14.8) 0.49
Bortezomib plus thalidomide-based 12/31 (39) 34.4 (13.9-NE) 19.4 (10.3-NE) 2.36 13/18 (72) 9.86 (5.42-14.9) 1.22 (0.49-2.86) 0.80
Bortezomib-based, no thalidomide/
lenalidomide
83/138 (60) 14.7 (10.5-19.1) 7.7 (4.6-11.7) 2.82 151/260 (58) 13.6 (11.2-14.9) 6.3 (4.6-8.1) 1.62
Other,c no bortezomib or thalidomide/
lenalidomide
12/26 (46) 17.2 (8.2-NE) 7.8 (1.3-NE) 2.28 79/141 (56) 15.4 (10.5-18.2) 4.3 (2.5-6.7) 1.26
Line 3
Thalidomide-based 5/14 (36) NE (NE-NE) NE (NE-NE) 0.92 24/50 (48) 11.6 (6.90-NE) 4.27 (0.92-8.71) 0.75
Lenalidomide-based 28/79 (35) 22.6 (18.2-NE) 4.44 (1.91-NE) 0.80 43/105 (41) 21.1 (13.0-26.0) 3.78 (1.61-7.66) 0.52
Bortezomib plus lenalidomide-based 4/12 (33) NE (NE-NE) NE (NE-NE) 1.32 5/10 (50) 36.1 (3.81-36.1) 7.89 (0.07-24.0) 0.78
Bortezomib plus thalidomide-based 6/11 (55) 14.1 (5.95-22.8) 6.74 (0.26-21.0) 1.72 6/11 (55) 8.16 (1.54-NE) 2.66 (0.20-4.11) 0.39
Bortezomib-based, no thalidomide/
lenalidomide
46/79 (58) 14.2 (9.4-19.5) 7.3 (4.0-12.6) 2.17 71/129 (55) 13.8 (9.7-17.1) 6.1 (3.3-9.9) 1.86
Other,c no bortezomib or thalidomide/
lenalidomide
17/39 (44) 13.2 (11.0-NE) 9.6 (2.2-NE) 1.97 102/174 (59) 12.0 (9.5-14.8) 3.4 (2.6-4.6) 1.08
Line 4e
Thalidomide-based 4/7 (57) 13.7 (3.94-NE) 1.05 (0.30-NE) 0.79 14/30 (47) 13.3 (9.23-NE) 6.74 (0.39-NE) 0.77
Lenalidomide-based 19/44 (43) 22.7 (14.8-28.9) 2.07 (1.28-12.1) 0.38 19/50 (38) 15.7 (10.5-27.0) 1.87 (1.38-4.70) 0.38
Bortezomib-based, no thalidomide/
lenalidomide
23/47 (49) 15.9 (9.0-26.7) 7.1 (2.3-20.4) 1.53 62/92 (67) 10.0 (7.6-12.3) 4.3 (2.5-5.3) 1.22
Other,c no bortezomib or thalidomide/
lenalidomide
23/36 (64) 7.4 (5.1-10.8) 2.2 (1.0-3.7) 1.26 46/105 (44) 10.1 (8.5-15.9) 2.6 (1.9-7.1) 0.74
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e412 - Clinical Lymphoma, Myeloma & Leukemia October 2018thalidomide/lenalidomide-based options within their ﬁrst few lines
of therapy. With the introduction of multiple new drugs, a
consensus of treatment sequences for MM now seems even more
remote, and choosing the best available therapy might be compro-
mised by the restrictions of drug access in multiple national settings.
This variation with subsequent lines of therapy is supported by an
analysis of MM practice patterns across Europe conducted in 2014.
Although bortezomib-containing combinations were identiﬁed as
the most commonly used induction regimen, with lenalidomide the
most frequently used agent in lines 2 and 3,10 greater variation was
seen in later lines, just as seen in the present study. Also, these
ﬁndings from the EMMOS and other European real-world studies
are not likely to be reﬂective of real-world practice in the United
States. In addition, speciﬁc centers of excellence might also have
their own treatment protocols, for example, to deﬁne risk stratiﬁ-
cation and treatment sequencing. Furthermore, the increased
number of regimens and approved agents for MM treatment is very
likely to have altered the current data with respect to the frequency
of use of different backbone agents in different treatment settings.
Regarding the speciﬁc treatment combinations, although still an
option in the relevant guidelines at the time of data collection,19,20
regimens such as MP have been thought to have been generally
superseded in routine clinical practice. However, our data showed
that several patients were still receiving them, most notably as ﬁrst-
and second-line therapy for patients not selected or not eligible for
SCT. However, this might reﬂect the timeline of approvals during
the EMMOS data collection, because combinations such as VMP
and MPT (melphalan, prednisolone, thalidomide) were still some-
what new at study start, resulting in cost and/or access barriers in
some countries. The current guidelines recommend 4 bortezomib-
based regimens with/without thalidomide/lenalidomide (VMP,
VCD, VTD, VRD [bortezomib, lenalidomide, dexamethasone])
and 2 nonebortezomib-based regimens (RD [lenalidomide, dexa-
methasone] and MPT) as frontline therapy.21
In general, patients in the SCT group had greater ORRs, with a
greater proportion achieving a VGPR or better compared with those in
the non-SCT group. For example, patients receiving frontline therapies
incorporating thalidomide/lenalidomide, with or without bortezomib,
had an ORR of 97% and 94%, respectively, in line with previously
reported rates in phase III clinical trials.22 High ORRs were also
observed with both frontline and salvage bortezomib-containing lines
across the SCT and non-SCT groups. The VGPR or better rates
observedwith frontline bortezomib in the SCTpopulationwere similar
to the rates reported with bortezomib-based induction therapy in SCT-
eligible patients in randomized phase III clinical trials,23-25 with the
caveat that the trials used standardized and stringent response criteria.
In general, however, the ORRs for each type of regimen decreased with
each subsequent therapy line. In the SCT population, bortezomib plus
thalidomide/lenalidomide regimens resulted in the numerically greatest
ORRs through line 3; however, in later lines ( 5), the ORRs for all
types of bortezomib- or thalidomide/lenalidomide-based therapies
were within 10% of each other.
In terms of the time-to-event outcomes, patients in the SCT group
had longer TTNT and TFI after frontline therapy than did their
counterparts in the non-SCT group, with a higher TFR in the SCT
group, suggesting that these patients were spending relatively less time
“on treatment.”However, in subsequent lines, these differences were
Mohamad Mohty et algenerally much less pronounced. In the SCT and non-SCT groups,
the TFR generally decreased with each subsequent line, suggesting
that patients were increasingly continuing treatment as they received
subsequent lines of therapy.26 Those patients receiving ‘other’ regi-
mens, however, had longer TTNT and TFI with second-line treat-
ment compared with frontline, which, although shorter in subsequent
lines, stayed largely greater than that seen in frontline. Overall, the
median treatment duration decreased in the SCT and non-SCT
groups with each subsequent line of therapy.
Because the EMMOS was a registry-based study, a number of
limitations should be considered. The data were limited by the
information available from the treating physicians as a part of
routine clinical practice; thus, parameters such as minimal residual
disease were not collected, and the rate of cytogenetic evaluation was
limited. It was also not possible to clearly determine the intentions
underlying the treatment choices. This is also linked to the fact that
comparisons between different regimen types must be interpreted
with caution, because the allocation of patients to a particular
intervention were not randomized and, thus, could have inﬂuenced
the outcomes. Additionally, regimens or agents could have been
used in different combinations and in different treatment ap-
proaches within or between lines of therapy and in different treat-
ment contexts (eg, as maintenance after autologous SCT); thus,
caution should be used in the interpretation of the ﬁndings between
the broad-based categories of regimens. Moreover, no standardized
response criteria were used across the sites, and no uniform
requirement for conﬁrmation of a complete response by bone
marrow analysis was included, making comparisons of response less
reliable. Also, the collection of safety data was limited by compar-
isons with clinical trial protocols, restricting the interpretation of
these data. Finally, owing to the timeframe of the EMMOS, with
the ﬁnal data collected in 2014, the recent rapid developments in
MM treatment options and assessment techniques could not be
reﬂected or incorporated. For example, the proteasome inhibitors
carﬁlzomib and ixazomib have been approved for the treatment of
relapsed/refractory MM,27,28 and the histone deacetylase inhibitor,
panobinostat, and the monoclonal antibodies daratumumab and
elotuzumab have also been approved.29,30
These factors do not diminish the usefulness of our data but
merely clarify the parameters of applicability. With the continued
approval of new agents, the information presented in the present
study can be expected to evolve, pointing to future changes in the
treatment paradigm and likely further improvements in patient
outcomes. It will be interesting to see, in subsequent evaluations,
how quickly recently approved agents actually become integrated
into standard real-world treatment practices. Access to novel agents
varies greatly from country to country, with factors such as
affordability, local guidelines and restrictions, and regulatory
decisions or delays all affecting treatment availability. The need for
robust health economic evaluations, in addition to efﬁcacy and
safety data, has become increasingly important in this respect.
Conclusion
These prospective real-world data highlight the large diversity of
treatments used to manage MM in normal practice. This was an
unexpected ﬁnding that was likely linked to various factors,including study duration, the large number of sites and countries
involved and their differing access to treatments, the diversity of
patients included in the registry, the approval and introduction of
new novel agents during the study period, and changes in treatment
recommendations over time. The results also provide insights into
the real-world clinical beneﬁts that can be achieved with both SCT
and systemic treatment regimens in MM, with efﬁcacy similar to
that seen in controlled clinical trials. Taken together, these data
provide a framework toward the design of future protocols aiming to
improve the outcomes in MM.
Clinical Practice Points
 MM, although treatable, remains an incurable disease, with a
dearth of evidence on how this disease is treated in real-world
clinical practice.
 Despite the availability of an increasing number of agents to treat
MM, objective, detailed knowledge is lacking on the natural
history of patients with MM at different stages of disease and on
treatment selection, dose, duration of therapy, outcomes, and
how practices vary from country to country.
 The present prospective, noninterventional observational study
found huge diversity in the treatment regimens used in everyday
clinical practice for MM.
 The present study has also described the efﬁcacy and provided
insights into treatment tolerability of patients with MM in
geographically diverse real-world settings.
 The present study has provided representative and descriptive
data to allow for health economic, pharmacoepidemiologic, and
outcomes research.
 These results provide a framework toward the design of future
protocols aiming to improve the outcomes of patients with MM
and identify imbalances in regional treatment strategies.Acknowledgments
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Galina Salogub (Saint Petersburg), Ludmila Magomedova (Mos-
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Martin Sanchez (Sevilla), Eduardo Rios-Herranz (Sevilla), Jeronima
Ibañez-Garcia (Murcia), Maria Jose Herranz (Tarragona), Belen
Hernandez (Ciudad Real), Sara Sanchez Sanchez (Alicante), Fer-
nando Escalante (Leon), Fernando Carnicero (Caceres), Joan Bargay
Lleonart (Palma De Mallorca), Mercedes Gironella (Barcelona),
Rafael Martínez (Madrid), Ana Lopez De La Guia (Madrid), Luis
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Ramos (Talavera De La Reina, Toledo), Javier De La Serna
(Madrid), Pedro Garcia Sanchez (Alicante), Juan Besalduch Vidal
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Supplemental Table 1 Summary of Data Collection
Data Collection
Retrospective
Demographic data and baseline disease characteristics
Physical examination
Treatment
All previous MM therapies, including start/stop dates
Rationale for treatment of MM-related complications
Concomitant medications
Effectiveness
Outcomes
Medical resource usage and health economics
Resource usage
Prospective
Demographic data and baseline disease characteristics
Sociodemographic data
Disease
Diagnosis history
Comorbidities
Disease severity
Current disease status
Treatment
Current MM treatment, including participating physician’s rationale for
treatment choice
Certain concomitant medications
Effectiveness
Response, including criteria used for assessment
Time-to-event endpoints
Medical resource usage and health economics
Resource usage and HRQL
Safety
All ADRs and AE (serious and not serious) in prospective phase; ADRs
related to bortezomib only in retrospective phase
Reason for early withdrawal from the study (where applicable)
Abbreviations: ADR ¼ adverse drug reaction; AE ¼ adverse event; HRQL ¼ health-related
quality of life; MM ¼ multiple myeloma.
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Supplemental Table 2 Frontline Therapy for SCT and Non-SCT Patients Stratiﬁed by High Versus Low 60-year Life Expectancy and
Age £ 65 Versus > 65 years Recorded During Prospective Data Collection Phasea and Based on Therapies
Received During Cycle 1
Regimen
SCT Patients
Non-SCT Patients
(n [ 906)
Frontline
(n [ 299)
Not Frontline
(n [ 81)
Total
(n [ 380)
All patients
Thalidomide/lenalidomide-based, no bortezomib 32 (10.7) 14 (17.3) 46 (12.1) 160 (17.7)
Bortezomib plus thalidomide/lenalidomide-based 108 (36.1) 6 (7.4) 114 (30.0) 34 (3.8)
Bortezomib-based, no thalidomide/lenalidomide 141 (47.2) 29 (35.8) 170 (44.7) 491 (54.2)
Other, no bortezomib or thalidomide/lenalidomide 18 (6.0) 32 (39.5) 50 (13.2) 221 (24.4)
High 60-y life expectancy countriesb
Patients, n 210 30 240 489
Thalidomide/lenalidomide-based, no bortezomib 2 (1.0) 0 2 (0.8) 47 (9.6)
Bortezomib plus thalidomide/lenalidomide-based 97 (46.2) 4 (13.3) 101 (42.1) 24 (4.9)
Bortezomib-based, no thalidomide/lenalidomide 107 (51.0) 23 (76.7) 130 (54.2) 379 (77.5)
Other, no bortezomib or thalidomide/lenalidomide 4 (1.9) 3 (10.0) 7 (2.9) 39 (8.0)
Low 60-y life expectancy countriesc
Patients, n 89 51 140 417
Thalidomide/lenalidomide-based, no bortezomib 30 (33.7) 14 (27.5) 44 (31.4) 113 (27.1)
Bortezomib plus thalidomide/lenalidomide-based 11 (12.4) 2 (3.9) 13 (9.3) 10 (2.4)
Bortezomib-based, no thalidomide/lenalidomide 34 (38.2) 6 (11.8) 40 (28.6) 112 (26.9)
Other, no bortezomib or thalidomide/lenalidomide 14 (15.7) 29 (56.9) 43 (30.7) 182 (43.6)
Patients aged  65 y
Patients, n 262 77 339 337
Thalidomide/lenalidomide-based, no bortezomib 31 (11.8) 13 (16.9) 44 (13.0) 67 (19.9)
Bortezomib plus thalidomide/lenalidomide-based 93 (35.5) 6 (7.8) 99 (29.2) 25 (7.4)
Bortezomib-based, no thalidomide/lenalidomide 121 (46.2) 27 (35.1) 148 (43.7) 124 (36.8)
Other, no bortezomib or thalidomide/lenalidomide 17 (6.5) 31 (40.3) 48 (14.2) 121 (35.9)
Patients aged > 65 y
Patients, n 37 4 41 569
Thalidomide/lenalidomide-based, no bortezomib 1 (2.7) 1 (25) 2 (4.9) 93 (16.3)
Bortezomib plus thalidomide/lenalidomide-based 15 (40.5) 0 15 (36.6) 9 (1.6)
Bortezomib-based, no thalidomide/lenalidomide 20 (54.1) 2 (50) 22 (53.7) 367 (64.5)
Other, no bortezomib or thalidomide/lenalidomide 1 (2.7) 1 (25) 2 (4.8) 100 (17.6)
Data presented as n (%); all percentages calculated from respective numbers within high or low 60-year life expectancy group.
Abbreviation: SCT ¼ stem cell transplantation.
aFor example, among patients who entered the study at the point of receiving their ﬁrst treatment line.
bAustria, France, Germany, Greece, Israel, Italy, Portugal, and Spain.
cAlgeria, Croatia, Denmark, Estonia, Hungary, Latvia, Lithuania, Macedonia, Poland, Russia, Slovenia, South-Africa, Turkey, and Ukraine.
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Supplemental Table 3 Salvage Therapies for SCT and Non-SCT Patients Stratiﬁed by Countries With High Versus Low 60-year Life Expectancy Recorded During prospective Data Collection
Phasea and Based on Therapies Received During Cycle 1
Treatment
SCT Patients (n [ 395) Non-SCT Patients (n [ 677)
Line 2
(n [ 345)
SCT in Lineb
(n [ 133)
Line 3
(n [ 288)
SCT in Lineb
(n [ 74)
Line ‡ 4
(n [ 458)
SCT in Lineb
(n [ 49)
Line 2
(n [ 805)
Line 3
(n [ 590)
Line ‡ 4
(n [ 481)
High 60-y life expectancy countriesc
Patients, n 198 62 178 38 297 22 405 266 101
Thalidomide/lenalidomide-based, no bortezomib 71 (35.9) 20 (32.3) 70 (39.3) 9 (23.7) 78 (26.3) 1 (4.5) 8 (2.0) 112 (42.1) 23 (22.8)
Bortezomib plus thalidomide/lenalidomide-based 23 (11.6) 8 (12.9) 15 (8.4) 9 (23.7) 15 (5.1) 2 (9.1) 7 (1.7) 2 (0.8) 5 (5.0)
Bortezomib-based, no thalidomide/lenalidomide 80 (40.4) 20 (32.3) 60 (33.7) 10 (26.3) 81 (27.3) 9 (40.9) 140 (34.6) 71 (26.7) 32 (31.7)
Other, no bortezomib or thalidomide/lenalidomide 24 (12.1) 13 (21.0) 33 (18.5) 10 (26.3) 123 (41.4) 10 (45.5) 61 (15.1) 81 (30.5) 41 (40.6)
Low 60-y life expectancy countriesd
Patients, n 147 71 110 36 158 27 400 324 380
Thalidomide/lenalidomide-based, no bortezomib 32 (21.8) 15 (21.1) 31 (28.2) 5 (13.9) 45 (28.5) 4 (14.8) 98 (24.5) 77 (23.8) 82 (25.3)
Bortezomib plus thalidomide/lenalidomide-based 18 (12.2) 10 (14.1) 8 (7.3) 2 (5.6) 13 (8.2) 2 (7.4) 13 (3.3) 11 (3.4) 15 (4.6)
Bortezomib-based, no thalidomide/lenalidomide 76 (51.7) 37 (52.1) 35 (31.8) 14 (38.9) 41 (25.9) 4 (14.8) 156 (39.0) 87 (26.9) 99 (30.6)
Other, no bortezomib or thalidomide/lenalidomide 21 (14.3) 9 (12.7) 36 (32.7) 15 (41.7) 59 (37.3) 17 (63.0) 133 (33.3) 149 (46.0) 184 (56.8)
Data presented as n (%); all percentages calculated from respective numbers within high or low 60-year life expectancy group.
Abbreviation: SCT ¼ stem cell transplantation.
aFor example, if a patient entered the study at the time of beginning line 3 of therapy, these data include the treatment regimens received by the patient at line 3 (and any subsequent lines), but not the information collected retrospectively on prior treatment (line 1, line 2) before
study enrollment.
b
“Line 2, SCT in Line” column contains data for all patients; “Line 3 SCT in Line” and “Line  4, SCT in Line” columns contain data only for patients aged < 65 years.
cAustria, France, Germany, Greece, Israel, Italy, Portugal, and Spain.
dAlgeria, Croatia, Denmark, Estonia, Hungary, Latvia, Lithuania, Macedonia, Poland, Russia, Slovenia, South Africa, Turkey, and Ukraine.
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Supplemental Table 4 Line-emergent AEs in SCT and Non-SCT Patients Stratiﬁed by Therapy Type
Variable
SCT Patients Non-SCT Patients
Patients, n Any AE SAE
AEs Leading
to Death Patients, n Any AE SAE
AE Leading
to Death
Line 1
Bortezomib-based, no thalidomide/lenalidomide 131 101 (77.1) 27 (20.6) 0 478 374 (78.2) 145 (30.3) 34 (7.1)
Bortezomib plus thalidomide-based 124 103 (83.1) 20 (16.1) 0 40 32 (80.0) 16 (40.0) 8 (20.0)
Bortezomib plus lenalidomide-based 27 22 (81.5) 8 (29.6) 1 (3.7) 19 17 (89.5) 6 (31.6) 1 (5.3)
Thalidomide/lenalidomide-based, no bortezomib 1 1 (100) 1 (100) 0 0 0 0 0
Other, no bortezomib or thalidomide/lenalidomide 37 16 (43.2) 3 (8.1) 0 190 101 (53.2) 39 (20.5) 13 (6.8)
Line 2
Bortezomib-based, no thalidomide/lenalidomide 148 95 (64.2) 30 (20.3) 12 (8.1) 290 171 (59.0) 68 (23.4) 21 (7.2)
Bortezomib plus thalidomide-based 31 23 (74.2) 1 (3.2) 0 21 9 (42.9) 5 (23.8) 2 (9.5)
Bortezomib plus lenalidomide-based 18 12 (66.7) 6 (33.3) 1 (5.6) 8 6 (75.0) 3 (37.5) 0
Thalidomide/lenalidomide-based, no bortezomib 1 1 (100) 1 (100) 0 1 1 (100) 0 0
Other, no bortezomib or thalidomide/lenalidomide 42 17 (40.5) 8 (19.0) 2 (4.8) 186 94 (50.5) 34 (18.3) 14 (7.5)
Line 3
Bortezomib-based, no thalidomide/lenalidomide 91 49 (53.8) 16 (17.6) 9 (9.9) 151 76 (50.3) 33 (21.9) 18 (11.9)
Bortezomib plus thalidomide-based 13 9 (69.2) 4 (30.8) 3 (23.1) 11 4 (36.4) 1 (9.1) 1 (9.1)
Bortezomib plus lenalidomide-based 15 10 (66.7) 5 (33.3) 1 (6.7) 10 8 (80.0) 7 (70.0) 2 (20.0)
Thalidomide/lenalidomide-based, no bortezomib 1 1 (100) 1 (100) 1 (100) 0 0 0 0
Other, no bortezomib or thalidomide/lenalidomide 66 28 (42.4) 14 (21.2) 5 (7.6) 227 117 (51.5) 46 (20.3) 22 (9.7)
Line 4
Bortezomib-based, no thalidomide/lenalidomide 57 39 (68.4) 17 (29.8) 8 (14.0) 111 67 (60.4) 29 (26.1) 9 (8.1)
Bortezomib plus thalidomide-based 7 4 (57.1) 0 0 9 9 (100) 4 (44.4) 2 (22.2)
Bortezomib plus lenalidomide-based 9 4 (44.4) 0 0 7 3 (42.9) 0 0
Thalidomide/lenalidomide-based, no bortezomib 0 0 0 0 1 1 (100) 0 0
Other, no bortezomib or thalidomide/lenalidomide 61 29 (47.5) 16 (26.2) 9 (14.8) 163 78 (47.9) 40 (24.5) 24 (14.7)
Line  5
Bortezomib-based, no thalidomide/lenalidomide 72 46 (63.9) 26 (36.1) 14 (19.4) 143 68 (47.6) 32 (22.4) 20 (14.0)
Bortezomib plus thalidomide-based 11 9 (81.8) 5 (45.5) 3 (27.3) 9 5 (55.6) 4 (44.4) 2 (22.2)
Bortezomib plus lenalidomide-based 11 8 (72.7) 3 (27.3) 2 (18.2) 13 6 (46.2) 3 (23.1) 2 (15.4)
Thalidomide/lenalidomide-based, no bortezomib 0 0 0 0 0 0 0 0
Other, no bortezomib or thalidomide/lenalidomide 125 72 (57.6) 48 (38.4) 28 (22.4) 259 128 (49.4) 71 (27.4) 31 (12.0)
Data presented as n (%).
Abbreviations: AE ¼ adverse event; SAE ¼ serious adverse event; SCT ¼ stem cell transplantation.
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